Dr. Stefan Glück, MD, FRCP(C), Ph.D., is a medical oncologist and Professor of Medicine, as well as, the Clinical Director of the BFBCI at UMSCCC. He coordinates clinical breast cancer services and clinical research for the BFBCI, as well as serves as a clinical liaison between basic and translational research and plays a major role in mentoring candidates in clinical trials and clinical aspects pertinent to translational research.
Dr. Glück is internationally known for his work on breast cancer, head and neck cancer and bone marrow transplant. He completed his medical studies at the Free University of West Berlin, Germany, where he subsequently did an internship. The internship was followed by residency in internal medicine at the Heinrich Heine Universität Düsseldorf, Germany, and a bone marrow transplant and medical oncology fellowship at the Princess Margaret Hospital, University of Toronto in Canada. Prior to his move to Miami, Dr. Glück was a Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, Professor with the Departments of Oncology, Medicine, Pharmacology, and Therapeutics at the University of Calgary in Alberta, and Deputy Head, Department of Oncology at the University of Calgary, Canada. Moreover, Dr. Glück has been awarded the Best Doctors in America honor which is a special merit earned based on a nationwide survey of over one million votes from his peers. This latter award warranted in less than 3 years of relocating to the United States. Dr. Glück has authored or co-authored over 150 articles, written or co-written several book chapters as well as countless journal abstracts, and has presented over 250 papers at national and international meetings. He is a member of several prestigious professional organizations and a reviewer for professional journals.
Dr. Glück has many years of experience as a clinical scientist running his own research lab and has an extensive background in Clinical Trials in breast cancer. His research in the past included the exploration of hematopoietic stem cell transplantation in breast cancer. He designed, performed and published a variety of Phase I, Phase II, and a major Phase III study, which was activated across Canada. It was one of his two instrumental studies that showed that high dose chemotherapy with stem cell transplantation for breast cancer can be safely delivered in an outpatient setting and proved that it does not improve the survival rate. His group was also the first one to show that the expression of the CRB2/HER2 soluble protein in patients with metastatic breast cancer predicts worse outcomes and can be used as a tumor marker for patients with HER2 positive breast cancer. Moreover, Dr. Glück’s group was the first in the world to show that ex vivo expansion of hematopoietic stem cell can lead to clinically relevant increases of the white cells in a period of recovery after stem cell transplantation.
Dr. Glück was also involved in the immunomodulation and immunotherapy of a variety of diseases, using the dendritic cell-based therapy, published widely in the generation and quality of these dendritic cells and how to use them in a CML, Lymphoma and Breast Cancer. In addition, Dr. Glück published several papers on circulating tumor cells, approximately ten years prior to the approval by the FDA to utilize such an approach as a predictor of therapy. Recently, he has focused on pharmacokinetic analysis and Phase I studies. One of the modern approaches how to deliver chemotherapy is a therapeutic drug monitoring (TDM), where patients are being dosed according to the clearance of a particular drug arrival or weight or height. At UMSCCC he focuses mainly on establishing collaboration in basic research in ethnic diversity, response to therapy in different patient population, as well the side effect profile. In collaboration with other members of the BFBCI, he is interested in